Kyntra Bio, Inc.
Kyntra Bio, Inc. (Nasdaq: KYNB) is a biopharmaceutical company developing therapies in oncology and anemia. Its oncology programs include FG-3246, a CD46-targeting antibody-drug conjugate in a Phase 2 study for metastatic castration-resistant prostate cancer, and FG-3180, a companion PET imaging agent being evaluated… From the company’s description.
Over the twelve months to Jun 30, 2026, Kyntra Bio, Inc. reported revenue of $4.62M and net income of $183.19M. Operations used $38.05M in cash. In fiscal 2025, it reported revenue of $6.44M, down 78.3% from fiscal 2024, and net income of $183.45M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Kyntra Bio, Inc. does
In the company’s own words
Kyntra Bio, Inc. (Nasdaq: KYNB) is a biopharmaceutical company developing therapies in oncology and anemia. Its oncology programs include FG-3246, a CD46-targeting antibody-drug conjugate in a Phase 2 study for metastatic castration-resistant prostate cancer, and FG-3180, a companion PET imaging agent being evaluated for tumor detection and patient selection. The company is also advancing roxadustat for anemia associated with lower-risk myelodysplastic syndromes and retains rights to the drug in the United States, Canada, Mexico and markets not assigned to partners. Roxadustat is approved for chronic kidney disease-related anemia in Europe, Japan, China and other countries, with Astellas commercializing it in Europe and Japan; Kyntra Bio sold its China operations and roxadustat rights there to AstraZeneca in 2025. The company’s programs are its primary business activities, rather than separately described reportable operating segments. Kyntra Bio was rebranded from FibroGen in January 2026, reflecting its focus on oncology and associated rare diseases. Its website is www.kyntrabio.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 921299
- SIC
- 2834
Financial performance, year by year
Fiscal 2015–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Kyntra Bio, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Kyntra Bio, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Kyntra Bio, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Kyntra Bio, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Kyntra Bio, Inc.'s last four quarterly filings that the numbers alone won't show?”